Introduction: The traditional goal of the treatment of Acute Myelogenous Leukemia is to produce and maintain a complete Remission (CR).The difference in survival time was entirely attributable to the duration of time spent in CR .In this study, the outcome of AML patients with allogeneic HSCT in CR1 versus other than CR1 was compared.Patients and Methods: Since March 1991 until November 2008, from 420 AML patients, 312 patients in CR1 with a median age of 28 years and 108 patients in other- than- CR1 with a median age of 27 years, have undergone allogeneic HSCT. The male/female ratio was 168/144 in the CR1 group and 55/53 in other- than- CR1. In totals 391 patients received Peripheral Blood, 27 patients Bone Marrow and 2 patients, Cord Blood as sources of HSCT.Results: At present, 266 (85%) patients in CR1 and 73 (68%) patients in other- than-CR1 are living. The most common cause of death in CR1 group was Graft Versus Host Disease and in the other- than CR1 group was relapse. Median follow up time was 17 months (range: 1-158 months). Six month Disease Free Survival (DFS) and Overall Survival (OS) in CR1 was 86% and 91% (SE=2%). 2-years DFS and OS in CR1 was 78% (SE=3%) and 85% (SE=2%). Six month DFS and OS in other- than- CR1 was 64% (SE=5%) and 75% (SE=4%). In this groups 2 years DFS and OS was 50% and 64% (SE=5%). It is to be noted that six month DFS and OS in transplanted patients with CR1 was significantly higher than in other- than- CR1 (p<0.001). Furthermore, 2-years DFS and OS in patients with CR1 were better than the second group (P< 0.001). Conclusion: Although the results of HSCT in other than first complete Remission is not as good as in first complete Remission, it seems that it is good enough to advise doing allogeneic HSCT for these patients.

Background and Aims: The combination of ulcerative colitis (UC) and end stage renal disease (ESRD) is uncommon. Immunosuppressive drugs that are used after kidney transplantation are considered as effective therapeutic alternatives for UC. We report two renal transplant recipients with long term refractory UC prior to kidney transplantation and confirmed by histological examination, cured following transplantation.Clinical Remission occurred immediately after kidney transplantation, and they had no symptoms of UC during 3 and 8 years of follow up periods. Their immunosuppression regimens were cyclosporine, mycophenolate mofetil / azathioprine and prednisone. In conclusion, kidney transplantation with immunosuppression leads to clinical Remission in patients with the inflammatory bowel diseases and ESRD.

Introduction: Atypical hemolytic uremic syndrome (HUS) is defined as a heterogeneous group of disorders. Plasma infusion or plasma exchange is the rescue therapy for this life-threatening syndrome. There is no evidence for the volume of plasma required to induce Remission. Materials and Methods: Between 2007 and 2018, Forty – two patients (M=20, F=22) with a diagnosis of recurrent or familial atypical hemolytic uremic syndrome (aHUS) who were admitted to Ali-Asgar Children’ s Hospital were enrolled in this observational retrospective study. The total volume of plasma required for normalizing platelet (>150000) and LDH (<500 IU), eliminating hemolysis, and decreasing serum creatinine at first presentation of disease was calculated. Patients with TTP, vasculitis, and post infectious HUS were excluded. Results: The mean age of the patients was 53 months (3-144 m). The majority of patients achieved Remission at first presentation by plasma infusion (5 under peritoneal dialysis and 4 under hemodialysis) but ten patients required plasmapheresis. A total of 980 units of FFP perfused with a total volume of 195. 975 L. The median (range) total plasma volume required for Remission was 166 ml/kg (43-2850 ml/kg). Conclusions: This study showed that the required plasma volume for the acute phase of atypical HUS for controlling the first attack of disease.